Increasing SAV1 levels to activate the tumor-suppressive Hippo pathway and inhibition of these oncogenic pathways resulted in robust inhibition of tumorigenicity, invasion, and metastasis of lung cancer cells, suggesting that use of exogenous agents to increase SAV1 levels in cancer presents a new strategy for discovering novel anticancer drugs. This evidence concerns the gene SAV1 and lung cancer.